| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10232124 | Current Opinion in Biotechnology | 2013 | 6 Pages |
Abstract
- Biologics based on monoclonal antibodies have dominated the clinical landscape.
- New knowledge of disease mechanisms is driving current drug discovery efforts.
- Ligands and receptors provide unique opportunities to manage biological complexity.
- Protein engineering is generating therapeutics with improved safety and efficacy.
Related Topics
Physical Sciences and Engineering
Chemical Engineering
Bioengineering
Authors
Mihalis S Kariolis, Shiven Kapur, Jennifer R Cochran,